Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the safety and the antiviral activity of two doses
of LB80380 for 48 weeks in treatment-naive patients with chronic hepatitis B infection
compared to entecavir 0.5 mg.